Insmed Q1 revenue up 23% to $92.8M; net loss widens to $1.42/sh; brensocatib PDUFA Aug 12

INSMED Inc

2025-Q1 EPS reported -$1.42 revenue$92,823,000

ARIKAYCE total revenue $92.8M (+23% YoY); FY2025 guidance reaffirmed $405-425M.
Net loss $256.6M ($1.42/sh) vs $157.1M ($1.06/sh); R&D $152.6M, SG&A $147.5M.
Brensocatib NDA accepted; PDUFA date Aug 12, 2025; EU/UK MAA accepted.
TPIP Phase 2b in PAH completed; topline data expected June 2025; Phase 3 in PH-ILD planned H2 2025.
$569.5M convertible notes redeemed; cash & securities $1.2B as of March 31.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.